Publications by authors named "Alan D Brooks"

Claim this Profile
R
Ring A/B-Modified 17β-Hydroxywithanolide Analogues as Antiproliferative Agents for Prostate Cancer and Potentiators of Immunotherapy for Renal Carcinoma and Melanoma.
E M Kithsiri Wijeratne, Ya-Ming Xu, Manping X Liu, Marielle C Inacio, Alan D Brooks

J Nat Prod· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins.
Poonam Tewary, Alan D Brooks, Ya-Ming Xu, E M Kithsiri Wijeratne, Ashley L Babyak

Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytotoxic and other withanolides from aeroponically grown Physalis philadelphica.
Ya-Ming Xu, E M Kithsiri Wijeratne, Alan D Brooks, Poonam Tewary, Li-Jiang Xuan

Phytochemistry· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.
Ya-Ming Xu, E M Kithsiri Wijeratne, Ashley L Babyak, Hanna R Marks, Alan D Brooks

J Nat Prod· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships.
Ya-Ming Xu, Alan D Brooks, E M Kithsiri Wijeratne, Curtis J Henrich, Poonam Tewary

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Anil Shanker, Samuel T Pellom, Duafalia F Dudimah, Menaka C Thounaojam, Rachel L de Kluyver, Alan D Brooks

Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cells.
Kevin T Sayers, Alan D Brooks, Thomas J Sayers, Oleg Chertov

PLoS One· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Curtis J Henrich, Cheryl L Thomas, Alan D Brooks, Nancy Lynn Booth, Evan M Lowery

Apoptosis· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Alan D Brooks, Kristen M Jacobsen, Wenqing Li, Anil Shanker, Thomas J Sayers

Mol Cancer Res· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.
Nancy Lynn Booth, Thomas J Sayers, Alan D Brooks, Cheryl L Thomas, Kristen Jacobsen

Cancer Immunol Immunother· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.
Anil Shanker, Alan D Brooks, Kristen M Jacobsen, John W Wine, Robert H Wiltrout

Cancer Res· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
Rosalba Salcedo, Julie A Hixon, Jimmy K Stauffer, Rashmi Jalah, Alan D Brooks

J Immunol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
Anil Shanker, Alan David Brooks, Carlos Alberto Tristan, John William Wine, Peter John Elliott

J Natl Cancer Inst· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
Karen Abdool, Erika Cretney, Alan D Brooks, Janice M Kelly, Jeremy Swann

J Immunol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.
Alan D Brooks, Teresa Ramirez, Uhi Toh, Jennifer Onksen, Peter J Elliott

Ann N Y Acad Sci· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis.
Alan D Brooks, Thomas J Sayers

Cancer Immunol Immunother· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Thomas J Sayers, Alan D Brooks, Crystal Y Koh, Weihong Ma, Naoko Seki

Blood· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Naoko Seki, Yoshihiro Hayakawa, Alan D Brooks, John Wine, Robert H Wiltrout

Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Naoko Seki, Alan D Brooks, Clive R D Carter, Timothy C Back, Erin M Parsoneault

J Immunol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis